<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0005">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="lis0005">
   <list-item id="lsti0005">
    <label>•</label>
    <p id="par0005">Baloxavir is an antiviral influenza medication with a different mechanism of action and its use in combination with oseltamivir has not been reported on patients with severe renal impairment.</p>
   </list-item>
   <list-item id="lsti0010">
    <label>•</label>
    <p id="par0010">Immunocompromise patients have a tendency to develop more severe forms of influenza infection. They may benefit from dual therapy.</p>
   </list-item>
   <list-item id="lsti0015">
    <label>•</label>
    <p id="par0015">Combination therapy may fasten overall recovery time and decrease the time on extracorporeal oxygenation support.</p>
   </list-item>
  </list>
 </p>
</abstract>
